Dyne Therapeutics, Inc. (DYN) Financials
DYN Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 165.1 million | 73.8 million |
2023-09-30 | 205.2 million | 53.2 million |
2023-06-30 | 251.4 million | 44.5 million |
2023-03-31 | 288.6 million | 46.7 million |
DYN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -35.1 million | 5.7 million |
2023-09-30 | -50.8 million | 4.9 million |
2023-06-30 | -55.9 million | 4.7 million |
2023-03-31 | -47.1 million | 4.6 million |
DYN Net Income
No data available :(
DYN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 123.1 million | - | 27.4 million |
2023-09-30 | 157.8 million | - | 28.2 million |
2023-06-30 | 207.7 million | - | 29.0 million |
2023-03-31 | 238.2 million | - | 29.8 million |
DYN Shares Outstanding
DYN Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 82000 | 58.8 million | 8.8 million | -567001 |
2023-09-30 | 167000 | 55.3 million | 7.0 million | - |
2023-06-30 | 250000 | 59.1 million | 7.6 million | - |
2023-03-31 | 230000 | 37.5 million | 7.9 million | - |
DYN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 3.8 million | 567000 |
2023-09-30 | - | 597000 |
2023-06-30 | - | 674000 |
2023-03-31 | - | 623000 |
DYN
Price: $26.08
52 week price:
Payout Ratio Range:
Earnings Per Share: -3.98 USD
P/E Ratio: -6.38
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 169300
Ebitda: 950.0 millionMarket Capitalization: 2.2 billion
Average Dividend Frequency: 4